Transcatheter aortic valve-in-valve implantation for failed surgical bioprostheses: results from Polish Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI) Registry

Bioprosthesis Transcatheter Aortic Valve Replacement Treatment Outcome Aortic Valve Humans Poland Registries Prosthesis Design 3. Good health
DOI: 10.20452/pamw.16149 Publication Date: 2021-11-30T18:20:44Z
ABSTRACT
KEy wORds aortic stenosis, transcatheter valve implantation, -in -valveAbsTRACT INTROduCTION Transcatheter -valve implantation (ViV -TAVI) has emerged as an alternative to redo surgery in patients with failed surgical bioprosthesis.ObjECTIvEs We evaluated the safety and efficacy of ViV -TAVI Polish after replacement.PATIENTs ANd mEThOds This was a nationwide multicenter registry procedures.Data were collected using online form, clinical follow -up lasted 1 year.REsuLTs From 2008 2020, 130 procedures performed (1.9% all [TAVI] cases).A considerable increase since 2018 been observed (n = 59, 45% cases).Hancock II, Freestyle, homograft most frequently treated bioprostheses.The self -expanding supra -annular Corevalve / Evolut used 76% cases.In 21% cases, mean postprocedural pressure gradient (PG) exceeded 20 mm Hg.All -cause mortality at year 10.8%.Aortic stenosis associated higher PG than regurgitation or mixed disease (P 0.004).Supra valves lower PGs intra 0.004).Second -generation devices shorter procedure time (120 min vs 135 min, P 0.04), less frequent need for additional TAVI (2% 10%, -year cardiovascular (95% 82.8%, 0.03) first valves.CONCLusIONs treatment bioprostheses is increasingly common, best hemodynamic effect shown valves.The introduction second improved procedural outcomes.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)